$1.77 Billion is the total value of Bain Capital Life Sciences Investors, LLC's 31 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $429,009,000 | -18.8% | 5,831,307 | -19.9% | 24.30% | -26.7% |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -1,431,058 | -100.0% | -1.10% | – |
| Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -10,895,773 | -100.0% | -3.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.